New VLA1553 vaccine may prevent chikungunya infection: Lancet
A new study published in the Lancet by Martina Schneider and team showed that VLA1553 is a strong candidate for the prevention of chikungunya virus illness since it elicited a robust immune response and the production of seroprotective titres in nearly all of the vaccines.
A live-attenuated vaccine option for active immunization and chikungunya virus illness prevention is VLA1553. Following immunization with VLA1553, this trial provided safety and immunogenicity data up to day 180.
43 accredited vaccination trial locations in the United States participated in this double-blind, randomized, multicentre, phase 3 study. Healthy volunteers who were at least 18 years old were eligible. VLA1553 or a placebo was given randomly (3:1) to each participant. The majority of patients having a baseline chikungunya virus antibody level that was seroprotective, as measured by a 50% plaque reduction in a micro plaque reduction neutralization test (μPRNT) with a PRNT50 titre of at least 150, 28 days after vaccination, was the main objective. Each and every person who received immunization was included in the safety analysis. At 12 pre-selected trial sites, immunogenicity studies were performed on a sample of subjects. For these subjects to be included in the per-protocol population for immunogenicity analysis, there may be no significant protocol violations.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.